Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Multiple coagulation factors (replacement) refers to therapeutic products used to replace one or more deficient blood clotting factors in individuals with bleeding disorders. These therapies are essential for managing conditions such as hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), von Willebrand disease, and other rare congenital or acquired factor deficiencies. Replacement therapy restores the missing factor(s), allowing normal clot formation.
Replaces deficient clotting factors, restoring the coagulation cascade and enabling clot formation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple Coagulation Factors (Replacement).